AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03695458 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
Study NCT03695458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
Study NCT02141022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasticity-based computerized cognitive remediation program
Study NCT02141022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gileyna
Study NCT02141022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gileyna
Study NCT04224207 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stem cell
Description: The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
Study NCT01915160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTF-CBT
Description: Standard treatment with the edition of in-treatment/session iPad activities.
Study NCT01915160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT
Description: Treatment as usual.
Study NCT04353128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 2mg
Description: 2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
Study NCT04353128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Identically looking placebo tablets P.O. before bedtime for 12 weeks
Study NCT01007357 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Body MR imaging
Description: Body MR imaging will be performed to optimize sequences
Study NCT03111836 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
Study NCT03111836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expert-Driven Group
Description: The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
Study NCT03955523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single exercise bout trial
Description: Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
Study NCT03955523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single diet trial
Description: Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
Study NCT03664934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Neck-specific exercises for chronic whiplash associated disorders
Study NCT00688870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
Study NCT03111836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: User-driven group
Description: The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
Study NCT00688870 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC)
Description: 7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
Study NCT02878005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction
Study NCT02180581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (2 * 10^9 cfu/day)
Description: Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months
Study NCT02180581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 months
Study NCT01425034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: casts for the thumb
Description: The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
Study NCT01425034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion group
Description: The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
Study NCT01402401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study NCT01402401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01931423 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placental cord drainage
Study NCT01548027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration group
Description: patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
Study NCT01548027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age > 6 months
Study NCT01548027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study NCT03997461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPro
Description: BPro and Oscar 2 comparison for 24 hours
Study NCT04394923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modification of the pulmonary vein ablation line
Description: The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
Study NCT04394923 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regular PVI ablation
Description: Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
Study NCT00988598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04447943
Description: 25 mg of PF-04447943 orally every 12 hours for 7 days
Study NCT00988598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
Study NCT02347397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SS Bipolar Head + SL-TWIN Stem
Description: Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem
Study NCT02347397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Head + SL-PLUS Stem
Description: Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
Study NCT02579668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Therapy
Study NCT03881111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study NCT03881111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study NCT03881111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
Study NCT03881111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
Study NCT03881111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
Study NCT03881111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
Study NCT01212562 — intervention group
Intervention type: PROCEDURE
Intervention: Immunocryosurgery
Description: Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once Daily, 7 Days
Study NCT02878005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain Laryngeal Mask
Description: Ambu AuraGain Laryngeal Mask
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsule, Oral, 25 mg, Once Daily, 7 days
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 50 mg, Single Dose, 1 day
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once daily, 6 days
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 50 mg, Once daily, 7 days
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once daily, 7 days
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 100 mg, Once daily, 7 days
Study NCT01250366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Study NCT04323176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village Model implementation
Description: Participate in the Village Model using a website
Study NCT03924440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proov (Ovulation Double Check) Test
Description: Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
Study NCT03014076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2 peptide + GM-CSF vaccine plus trastuzumab
Description: HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
Study NCT03014076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
Study NCT02094287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimetindene
Description: receiving either dimetindene or a placebo (saline) via infusion
Study NCT02094287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
Study NCT02094287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioning
Description: classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
Study NCT04078243 — intervention group
Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
Study NCT02920437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four-week weekly intervention to reduce salt intake
Description: The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
Study NCT02920437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual government pamphlets
Description: The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
Study NCT02103244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin will be dosed according to newly developed dosing algorithm.
Study NCT00700492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: vaginal capsules 3X200mg daily
Study NCT03259373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Patient-Level and Provider-Level Educational Intervention
Description: Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation.
Study NCT03259373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Provider-Level Educational Intervention
Description: Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
Study NCT04294927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingectomy with delayed oophorectomy
Description: * BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~* BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~* BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)
Study NCT04294927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk-reducing salpingo-oophorectomy
Description: * BRCA1 at a maximum age of 40 (advised between age 35 and 40)~* BRCA2 at a maximum age of 45 (advised between age 40 and 45)~* BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)
Study NCT02008851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-kidney augment
Description: Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
Study NCT02832401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Study NCT02832401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03950050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.
Study NCT02086604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Study NCT02086604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01857128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drawtex dressing
Study NCT01857128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Study NCT01769651 — intervention group
Intervention type: OTHER
Intervention: methadone replacement therapy
Description: Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
Study NCT01917539 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
Study NCT01917539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Light Therapy
Description: Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
Study NCT00888628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Pancreatic Islets
Description: Islet after kidney transplant in patients with type I diabetes.
Study NCT00888628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Given as induction for islet cell transplant
Study NCT02338973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Study NCT02442336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Journey AHead
Description: The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
Study NCT02099045 — intervention group
Intervention type: DEVICE
Intervention: Point of Care Ultrasonography
Study NCT00844532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absolute Pro™ Peripheral Self-Expanding Stent System
Description: Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
Study NCT03374527 — intervention group
Intervention type: OTHER
Intervention: blood sample collection
Description: Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
Study NCT03374527 — intervention group
Intervention type: PROCEDURE
Intervention: Synovial Fluid collection
Description: Synovial fluid is collected when prescribed in patients with psoriatic arthritis
Study NCT02505438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00749034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: live vaccine
Study NCT00749034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG
Study NCT04621513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture (RJ laser S/N 1813458)
Description: use a low-level-laser acupuncture on acupoint
Study NCT04621513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: western medicine
Description: Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
Study NCT04621513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: western medicine
Description: Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
Study NCT01124331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation target range (91%-95%)
Description: higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
Study NCT01124331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower oxygen saturation (85%-89%)
Description: Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter